Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
--
P/B Ratio
1.18
Industry P/E
--
Debt to Equity
0.54
ROE
-4.66 %
ROCE
-216.64 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-40.81 Mln
EBITDA
$-60.54 Mln
Net Profit
$-66.88 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mainz Biomed BV (MYNZ)
| -25.93 | -30.13 | -27.44 | -90.79 | -81.60 | -- | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Mainz Biomed BV (MYNZ)
| -83.66 | -31.67 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a... stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany. Address: Robert Koch Strasse 50, Mainz, Germany, 55129 Read more
CEO & Executive Director
Mr. Guido Baechler
CEO & Executive Director
Mr. Guido Baechler
Headquarters
Mainz
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mainz Biomed BV (MYNZ) stood at $ 13 Mln as on 31-Dec-24
The share price of Mainz Biomed BV (MYNZ) is $3.20 (NASDAQ) as of 24-Apr-2025 16:14 EDT. Mainz Biomed BV (MYNZ) has given a return of -81.6% in the last 3 years.
Mainz Biomed BV (MYNZ) has a market capitalisation of $ 7 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Mainz Biomed BV (MYNZ) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mainz Biomed BV (MYNZ) and enter the required number of quantities and click on buy to purchase the shares of Mainz Biomed BV (MYNZ).
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany. Address: Robert Koch Strasse 50, Mainz, Germany, 55129
The CEO & director of Mr. Guido Baechler. is Mainz Biomed BV (MYNZ), and CFO & Sr. VP is Mr. Guido Baechler.
There is no promoter pledging in Mainz Biomed BV (MYNZ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Mainz Biomed BV (MYNZ) | Ratios |
|---|---|
|
Return on equity(%)
|
-465.82
|
|
Operating margin(%)
|
-2301.53
|
|
Net Margin(%)
|
-2421.8
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mainz Biomed BV (MYNZ) was $0 Mln.
$0.05
(
